Study flowchart.

Abstract

After 1:1:2 propensity score matching, there were 921 patients treated with empagliflozin, 921 patients treated with dapagliflozin, and 1,842 patients treated with DPP4i (control group). ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DPP4i, dipeptidyl peptidase-4 inhibitor; HF, heart failure; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p